𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus

✍ Scribed by Morris Reichlin; James Fesmire; Ana I. Quintero-Del-Rio; Marianne Wolfson-Reichlin


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
67 KB
Volume
46
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Objective

To demonstrate the binding of bovine lipoprotein lipase (LPL) by IgG from sera obtained from patients with systemic lupus erythematosus (SLE) and other rheumatic diseases, and the relationship of anti‐LPL to triglyceride levels in SLE.

Method

Binding of LPL by IgG from sera obtained from patients with SLE and other rheumatic diseases was measured by an enzyme‐linked immunosorbent assay technique. Lipid profiles for fasting blood samples obtained from SLE patients and control subjects were determined.

Results

Sera obtained from 105 patients with SLE were assessed for reactivity with LPL, and 49 (47%) of the results were positive. Sera obtained from patients with rheumatoid arthritis (RA) (n = 80), Sjögren's syndrome (n = 30), polymyositis and dermatomyositis (n = 30), and progressive systemic sclerosis (n = 31) were also studied, and 10 (13%), 3 (10%), 12 (40%), and 13 (42%), respectively, were positive for reactivity with LPL. It was determined that all affinity‐purified anti–double‐stranded DNA (dsDNA) antibodies and 4 of 5 monoclonal anti‐dsDNA antibodies bound to LPL. The binding of IgG depleted of anti‐dsDNA to LPL indicates a second anti‐LPL activity in SLE. Measurements of fasting lipid levels in SLE patients with anti‐LPL revealed a strong positive correlation of antibody levels and total serum triglycerides, apolipoprotein B, and apolipoprotein E concentrations.

Conclusion

Antibodies to LPL occurred in 47% of SLE patients and in a similar percentage of patients with polymyositis or systemic sclerosis. The prevalence of these antibodies was less in patients with RA or Sjögren's syndrome. It is hypothesized that the elevated triglyceride levels in SLE patients are in part attributable to anti‐LPL, and this lipid abnormality could contribute to the premature atherosclerosis known to be present in patients with SLE.


📜 SIMILAR VOLUMES


Anti–lipoprotein lipase antibodies: A ne
✍ Jozélio Freire de Carvalho; Eduardo Ferreira Borba; Vilma Santos Trindade Viana; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

## Abstract ## Objective The novel description of antibodies to lipoprotein lipase (anti‐LPL) associated with dyslipoproteinemia prompted us to analyze the association of anti‐LPL with clinical and serologic features in patients with systemic lupus erythematosus (SLE) and its link to markers of in

Relationships of hla-dr and mt antigens
✍ Alejandro Alvarellos; Joseph M. Ahearn; Thomas T. Provost; Carole A Dorsch; Mary 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB 👁 2 views

have excluded this index from our nutritional assessment as its use may not be valid in patients with inflammatory joint disease. In addition, we have found significantly lower serum levels of albumin, transferrin, zinc, and folic acid in the RA patients, 12 (30%) of whom had combined anthropometri

Effects of short-term infliximab therapy
✍ Martin Aringer; Günter Steiner; Winfried B. Graninger; Elisabeth Höfler; Carl W. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

Objective. To analyze changes in autoantibodies occurring in patients with systemic lupus erythematosus (SLE) treated with 4 infusions of the chimeric anti-tumor necrosis factor ␣ (TNF␣) antibody infliximab. Methods. In an open-label safety study, 7 patients with SLE were treated with infliximab at